Incorporation of Brentuximab Vedotin in the Treatment of Lymphoma: Current Evidence and  Potential Use in Indonesia

Ibnu Purwanto

doi:10.22146/actainterna.61344

Incorporation of Brentuximab Vedotin in the Treatment of Lymphoma: Current Evidence and Potential Use in Indonesia

https://doi.org/10.22146/actainterna.61344

Ibnu Purwanto^(1*)

(1) Universitas Gadjah Mada/Dr Sardjito General Hospital
(*) Corresponding Author

Abstract

Although scientific advances have resulted in significantly improved survival among lymphoma patients, certain subsets of lymphoma patients still have poor prognosis, which includes relapsed and treatment refractory patients. Brentuximab vedotin, an anti-CD30 targeted therapy has shown remarkable results given in both Hodgkin and non-Hodgkin lymphoma, even in cases without CD30 expression. Unfortunately, evidence of its effectiveness in Indonesian patient is still limited as there is only 1 case report of such subject published.

Conclusion: Brentuximab vedotin, an anti-CD30 targeted therapy presents as an effective therapeutic option for relapsed and treatment refractory lymphoma patients.

Keywords

Lymphoma, brentuximab, CD30, Indonesia

Full Text:

PDF

References

Ferlay J, Soerjomataram I, Dikshit R, Eser R, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar; 136(5):E359-86. 2. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol. 2012 Sep; 30(27): 3383-8. 3. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar; 109(5): 185761. 4. DeVita VT. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 8th ed. DeVita VT, Lawrence TS, Rosenberg SA, editors. Philadelphia: Lippincott William & Wilkins; 2008. 5. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr; 121(14): 2715-24. 6. Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B-cell lymphoma: a populationbased study from British Columbia. Br J Haematol. 2014 Dec; 167(5): 608-17. 7. Onaindia A, Martínez N, Montes-Moreno S, Almaraz C, Rodríguez-Pinilla SM, et al. CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified. Am J Surg Pathol. 2016 Mar; 40(3): 378-85. 8. van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017 Sep; 7(9): e603. 9. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012 Jun; 30(18): 2183-9. 10. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo controlled, phase 3 trial. Lancet. 2015 May;385(9980): 1853-62. 11. Nademanee A, Sureda A, Stiff P, Holowiecki J, Abidi M, et al. Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting. Biol Blood Marrow Transplant. 2018 May; pii: S1083-8791(18)30298-2. 12. Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML. Brentuximab vedotin withgemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 Sep; 19(9): 1229-38. 13. Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, et al. Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial. J Clin Oncol. 2015; 33(15 Suppl.): 8505. 14. Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep; 128(11): 1458-64. 15. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018 Jan; 378(4): 331 44.2018 Jan; 378(4): 331-44. 16. Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomized trial by the German Hodgkin Study Group. Lancet Oncol. 2017 Dec;18(12): 1680-7. 17. Gibb A, Pirrie S, Linton K, Paterson K, Davies A, et al. Results of a phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVITY). Hemmatol Oncol. 2017;35(Suppl.2): 80–81. 18. Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb; 125(9): 1394-402. 19. Yasenchak CA, Farber CM, Budde LE, Ansell SM, Advani R, et al. Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. Blood. 2014; 124(21): 1745. 20. Purwanto I, Utomo BP, Ghozali A. Complete Remission of Relapsed Hodgkin’s Lymphoma Following Brentuximab Vedotin and Gemcitabine Combination Therapy With Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report. Case Rep Oncol. 2020; 13(1): 341-6. 21. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014; 123(20): 3095–100. 22. Ra nuha r dy D, Suz a nna E, Sari RM, Hadisantoso DW, Andalucia R, Abdillah A. CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). Acta Med Indonesia. 2018 Apr; 50(2): 104-9.

DOI: https://doi.org/10.22146/actainterna.61344